Company intelligence / Profile preview

OdeliaCures

Boston, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Odylia Therapeutics is a nonprofit biotech focused on developing and advancing gene therapies for rare diseases that lack available treatments. The organization emphasizes accelerating timelines and reducing costs by partnering with patient groups and leveraging a nonprofit model. Their primary area of activity involves bringing AAV-based gene therapies for rare inherited eye disorders into clinical development, though specific trial results are not detailed in the search results.

Therapeutic areas: OphthalmologyRare Diseases
Modalities: Gene therapyAAV-based gene therapy (Adeno-associated virus)
Industry: Biotech

Partnerships

Patient advocacy groups for rare disease drug development support and empowerment

Beyond the preview

Go deeper on OdeliaCures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OdeliaCures.

Explore the full profile